How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

544 results for

Famciclovir

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Treatment with valacyclovir, famciclovir, or antiretrovirals reduces human herpesvirus-8 replication in HIV-1 seropositive men. (PubMed)

Treatment with valacyclovir, famciclovir, or antiretrovirals reduces human herpesvirus-8 replication in HIV-1 seropositive men. Human herpesvirus-8 (HHV-8) replication is a key factor in Kaposi sarcoma, primary effusion lymphoma, and Castleman disease pathogenesis. In vitro data suggest that antivirals inhibit HHV-8 replication, but little data exist in humans. Daily oropharyngeal swabs were analyzed from HIV/HHV-8 dually infected men enrolled in three previous clinical trials of valacyclovir (...) and famciclovir for HIV-1 and/or HSV-2 suppression. Fifty-eight participants contributed 6,036 swabs. HHV-8 was detected in 1,128 (19%) of 6,036 swabs, including 618 (21%) of 2,992 on placebo, 323 (15%) of 2,221 on valacyclovir, and 187 (23%) of 823 on famciclovir. After adjusting for baseline HIV viral load and highly active antiretroviral therapy (HAART) use, an 18% reduction in HHV-8 shedding frequency (IRR 0.822; P = 0.011) was found in participants on valacyclovir and a 30% reduction (IRR 0.700; P

Full Text available with Trip Pro

2011 Journal of medical virology

22. Safety and Efficacy of Famciclovir in HIV1 Positive Adults With Recurrent Genital Herpes

Safety and Efficacy of Famciclovir in HIV1 Positive Adults With Recurrent Genital Herpes Safety and Efficacy of Famciclovir in HIV1 Positive Adults With Recurrent Genital Herpes - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Safety and Efficacy of Famciclovir in HIV1 Positive Adults With Recurrent Genital Herpes The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01154543 Recruitment Status : Completed First Posted : July 1, 2010 Last Update Posted : March 20, 2013 Sponsor: Holdsworth House Medical

2010 Clinical Trials

23. One-day famciclovir vs. placebo in patient-initiated episodic treatment of recurrent genital herpes in immunocompetent Black patients. (PubMed)

One-day famciclovir vs. placebo in patient-initiated episodic treatment of recurrent genital herpes in immunocompetent Black patients. There are no known racial differences in genital herpes disease pathogenesis or response to therapy. Despite high herpes simplex virus (HSV) seroprevalence in Black persons, clinical trials investigating the treatment of recurrent genital herpes (RGH) have typically enrolled a small proportion of Black patients.This multicenter, double-blind, placebo-controlled (...) study evaluated the efficacy and safety of patient-initiated, 1-day famciclovir 1000 mg twice-daily in immunocompetent Black adults (USA and South Africa) with RGH. Eligible patients were randomized (2:1) to famciclovir or placebo. The primary endpoint was time to healing of non-aborted genital herpes lesions (i.e., lesions that progressed beyond papule stage). Secondary endpoints included proportion of patients with aborted genital herpes lesions, time to resolution of associated symptoms

2010 Current medical research and opinion

24. Viral rash in pregnancy

, and Famciclovir in the First Trimester of Pregnancy and the Risk of Birth Defects. JAMA. 2010 Aug; 304(8): 859-66. 64. Wallace MR, Bowler WA, Murray NB, Brodine SK, Oldfield EC, III. Treatment of adult varicella with oral acyclovir. A randomized, placebo-controlled trial. Ann Intern Med 1992 Sep 1;117(5):358-63. 65. Cohen J, Breuer J. Chickenpox: treatment. Clinical Evidence 2015 Jun;06:912. 66. Kempf W, Meylan P, Gerber S, Aebi C, Agosti R, Buchner S, et al. Swiss recommendations for the management

2019 Public Health England

25. Herpes simplex infection

lesions involving the oropharynx and perioral mucosa. Aciclovir, famciclovir, and valaciclovir are effective at shortening the duration and severity of an outbreak. Daily suppressive therapy reduces recurrences by 80% and reduces transmission risk by approximately 50%. HSV type-specific antibody tests are used to diagnose infection with or without lesions and distinguish between type 1 and 2. Definition Infection with HSV-1 or HSV-2 can cause oral, genital, and ocular ulcers. The primary episode

2018 BMJ Best Practice

26. Acyclovir

were included in this systematic review. One provided weak evidence that acyclovir is an effective 2010 7. A comparative study to evaluate the efficacy and safety of acyclovir and famciclovir in the management of herpes zoster. 24551671 2014 02 19 2014 02 19 2017 02 20 2249-782X 7 12 2013 Dec Journal of clinical and diagnostic research : JCDR J Clin Diagn Res A comparative study to evaluate the efficacy and safety of acyclovir and famciclovir in the management of herpes zoster. 2904-7 10.7860/JCDR (...) /2013/7884.3670 Over the years, acyclovir has been the oral antiviral agent approved for the treatment (...) of patients with acute herpes zoster,Its effectiveness in lessening the acute signs and symptoms of herpes zoster has been established but the effects on post herpetic neuralgia are less clear cut. Famciclovir is a new member of guanine nucleoside family of drugs. It is a well absorbed oral form of penciclovir with longer half life. This was a open comparative randomized study carried out

2018 Trip Latest and Greatest

27. Celecoxib

thrice daily, or naproxen 375-500mg twice daily. All patients were provided with a proton pump inhibitor. The outcome was major NSAID toxicity, including time to first occurrence of major adverse cardiovascular events, important gastrointestinal events, renal events and all-cause mortality. RESULTS 2017 12. A famciclovir + celecoxib combination treatment is safe and efficacious in the treatment of fibromyalgia. 28260944 2017 03 06 2017 03 09 10 2017 Journal of pain research J Pain Res A famciclovir (...) + celecoxib combination treatment is safe and efficacious in the treatment of fibromyalgia. 451-460 10.2147/JPR.S127288 Infections and other stressors have been implicated in the development of fibromyalgia. We hypothesized that these stressors could result in recurrent reactivations of latent herpes (...) virus infections, which could lead to the development of fibromyalgia. This study evaluated a famciclovir + celecoxib drug combination (IMC-1), active against suspected herpes virus reactivation

2018 Trip Latest and Greatest

28. Is there any evidence that use of aciclovir/famciclovir reduces the risk of postherpetic neuralgia after shingles?

Is there any evidence that use of aciclovir/famciclovir reduces the risk of postherpetic neuralgia after shingles? Is there any evidence that use of aciclovir/famciclovir reduces the risk of postherpetic neuralgia after shingles? - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere (...) clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Is there any evidence that use of aciclovir/famciclovir reduces the risk of postherpetic neuralgia after shingles? Clinical Evidence contains a chapter on postherpetic neuralgia (1

2008 TRIP Answers

29. Herpes Zoster Ophthalmicus (HZO)

ulceration can lead to perforation anterior uveitis present IOP raised A1: for acute skin lesions: emergency referral (same day) to GP for systemic anti-viral treatment Early treatment with aciclovir (within 72 hours after rash onset) reduces the percentage of eye disorders in ophthalmic zoster patients from 50% to 20-30%. This early treatment also lessens acute pain Possible management by ophthalmologist Systemic anti-virals e.g. aciclovir, famciclovir, valaciclovir Topical anti-virals (off-licence use

2018 College of Optometrists

30. CRACKCast E120 – Dermatologic presentations

and are typically transmitted primarily by sexual contact. Secondary HSV generalization (in patients with atopic dermatitis) Secondary bacterial infection Dehydration (gingivostomatitis – in children with HSV1) Cervical carcinoma (HSV 2 associated infections) Death (mucocutaneous herpes infection in immunocompromised patients (including neonates!) can become generalized and then disseminated to internal organs) Recommended treatment for a first clinical episode of genital herpes is with acyclovir, famciclovir (...) Hunt syndrome is felt generally to be more severe than Bell’s palsy attributed to HSV, with increased rates of late neural denervation and a decreased probability of complete recovery (UTD) [24] What is the treatment of herpes zoster? Antiviral medications are indicated, especially within <72 hours of onset of rash, to decrease the duration of symptoms and associated pain. Antiviral therapy may be initiated with acyclovir, famciclovir, or valacyclovir. [Uptodate recommends continuing administration

2017 CandiEM

31. CRACKCast E071 – Ophthalmology Part A

and recognized immediately, herpes zoster of the eye may result in acute necrotizing retinitis and vision loss.” – Rosen’s 7th Ed. Involvement of the nasociliary branch —> Hutchinson’s sign Vesicles on the tip of the nose 75% risk of ocular involvement *** If not recognized leads to acute necrotizing retinitis and vision loss*** Treatment: Antivirals: acyclovir/valacyclovir/famciclovir ideally within 72 hrs Topical steroid agents Topical antibiotics (prevent secondary infection) Analgesia Cool compresses

2017 CandiEM

32. WHO guidelines for the treatment of Genital Herpes Simplex Virus

. Strong recommendation, moderate quality evidence For adults and adolescents with a first clinical episode of genital HSV infection, the WHO STI guideline suggests a standard dose of aciclovir over valaciclovir or famciclovir. Dosages: • aciclovir 400 mg orally thrice daily for 10 days (standard dose) • aciclovir 200 mg orally five times daily for 10 days • valaciclovir 500 mg orally twice daily for 10 days • famciclovir 250 mg orally thrice daily for 10 days Remarks: Given that follow-up visits may (...) not be possible during the course of treatment and symptoms of the first clinical episode may be prolonged, therapy is provided for 10 days. Although the benefits of the medicines are probably similar, the costs of valaciclovir and famciclovir are higher than aciclovir, and therefore aciclovir is preferred. The choice of medicine may also depend on compliance considerations. This recommendation also applies to people living with HIV, people who are immunocompromised, people with a severe episode and pregnant

2016 World Health Organisation Guidelines

33. Population pharmacokinetics and optimal design of paediatric studies for famciclovir (PubMed)

Population pharmacokinetics and optimal design of paediatric studies for famciclovir To develop a population pharmacokinetic model for penciclovir (famciclovir is a prodrug of penciclovir) in adults and children and suggest an appropriate dose for children. Furthermore, to develop a limited sampling design based on sampling windows for three different paediatric age groups (1-2, 2-5 and 5-12 years) using an adequate number of subjects for future pharmacokinetic studies.Penciclovir plasma data

Full Text available with Trip Pro

2009 British journal of clinical pharmacology

34. Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis

Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00878072 Recruitment Status : Completed First Posted : April 8, 2009 Last Update

2009 Clinical Trials

35. Famciclovir 500 mg Tablets Under Non-Fasting Conditions

Famciclovir 500 mg Tablets Under Non-Fasting Conditions Famciclovir 500 mg Tablets Under Non-Fasting Conditions - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Famciclovir 500 mg Tablets Under Non-Fasting (...) Study Description Go to Brief Summary: The objective of this study is to compare the relative bioavailability of famciclovir 500 mg tablets (Novopharm Limited) with that of FAMVIR® 500 mg tablets (Novartis) in healthy adult subjects under non-fasting conditions. Condition or disease Intervention/treatment Phase Healthy Drug: Famciclovir 500 mg Tablets Drug: Famvir® 500 mg Tablets Phase 1 Detailed Description: Criteria for Evaluation: FDA Bioequivalence Criteria Statistical Methods: FDA

2009 Clinical Trials

36. Famciclovir 500 mg Tablets Under Fasting Conditions

Famciclovir 500 mg Tablets Under Fasting Conditions Famciclovir 500 mg Tablets Under Fasting Conditions - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Famciclovir 500 mg Tablets Under Fasting Conditions (...) Description Go to Brief Summary: The objective of this study is to compare the relative bioavailability of famciclovir 500 mg tablets (Novopharm Limited) with that of FAMVIR® 500 mg tablets (Novartis) in healthy adult subjects under fasting conditions. Condition or disease Intervention/treatment Phase Healthy Drug: Famciclovir 500 mg Tablets Drug: Famvir® 500 mg Tablets Phase 1 Detailed Description: Criteria for Evaluation: FDA Bioequivalence Criteria Statistical Methods: FDA bioequivalence statistical

2009 Clinical Trials

37. Single-day famciclovir for the treatment of genital herpes: follow-up results of time to next recurrence and assessment of antiviral resistance. (PubMed)

Single-day famciclovir for the treatment of genital herpes: follow-up results of time to next recurrence and assessment of antiviral resistance. Episodic therapy of genital herpes is usually recommended for patients with infrequent symptomatic recurrences and where transmission is not a concern. While shorter courses are as effective as standard 5-day regimens, it is unknown whether abbreviated therapy has detrimental effects on natural history and the development of antiviral resistance.To (...) assess time to next recurrence and development of antiviral resistance in patients with recurrent genital herpes treated with either single-day famciclovir (1 g twice-daily) or 3-day valacyclovir (500 mg twice-daily).Longer-term, follow-up data on the time to next recurrence and antiviral sensitivity were collected from a previously reported multicenter, multinational, double-blind, parallel group study in which 1179 immunocompetent adults were randomized 1 : 1 to receive either single-day

Full Text available with Trip Pro

2009 Current medical research and opinion

38. Safety and effectiveness of the herpes zoster vaccine to prevent postherpetic neuralgia: 2014 update and consensus statement from the Canadian Pain Society

it be given to individuals who are taking high doses of corticosteroids (>20 mg/day of prednisone) or other immunosuppressive drugs. POSITION 3 Drug treatment (eg, antivirals, corticosteroids) of active shingles has not been shown to decrease the risk of PHN Rationale: Shingles can be treated with antiviral drugs such as acyclovir, famciclovir and valacyclovir. However, these drugs are effective only if given within 72 h of the first signs of the initial pain or rash. Antivirals have been shown

2015 CPG Infobase

39. Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients. (PubMed)

Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients. Genital herpes is caused by herpes simplex virus 1 (HSV-1) or 2 (HSV-2). Some infected people experience outbreaks of genital herpes, typically, characterized by vesicular and erosive localized painful genital lesions.To compare the effectiveness and safety of three oral antiviral drugs (acyclovir, famciclovir and valacyclovir) prescribed to suppress genital herpes outbreaks in non (...) trials including patients with recurrent genital herpes caused by HSV, whatever the type (HSV-1, HSV-2, or undetermined), with at least four recurrences per year (trials concerning human immunodeficiency virus (HIV)-positive patients or pregnant women were not eligible) and comparing suppressive oral antiviral treatment with oral acyclovir, famciclovir, and valacyclovir versus placebo or another suppressive oral antiviral treatment.Two review authors independently selected eligible trials

Full Text available with Trip Pro

2014 Cochrane

40. Antiviral treatment for preventing postherpetic neuralgia. (PubMed)

) of antiviral treatment given within 72 hours after the onset of herpes zoster for preventing PHN. There were no language restrictions.Two authors independently selected trials, evaluated the risk of bias in included trials, and extracted and analysed data.Six RCTs with a total of 1211 participants were eligible; five trials evaluated oral aciclovir, and one, with 419 participants, evaluated oral famciclovir. We were able to conduct meta-analyses as there were sufficient similarities in the included studies (...) ). In four of the trials (692 participants), there was some evidence for a reduction in the incidence of pain four weeks after the onset of rash. In the trial of famciclovir versus placebo, neither 500 mg nor 750 mg doses of famciclovir reduced the incidence of herpetic neuralgia significantly. The most commonly reported adverse events were nausea, vomiting, diarrhoea and headache for aciclovir, and headache and nausea for famciclovir. For neither treatment was the incidence of adverse events

2014 Cochrane

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>